

A. Rosowsky
U.S.S.N.: 09/890,112
Page 12

REMARKS

The Applicants appreciate the Examiner's thorough examination of the subject application. Applicants request reconsideration of the subject application based on the following remarks.

Claims 1, 3-12, 14-26, 28-34 are currently pending in the application. Claims 5, 11, 12, and 18-21 have been amended. No new matter has been added by the amendments to the specification or the claims.

Applicants appreciate the indication that claims 1, 3, 4, 7, and 10 are in a condition for allowance and that claims 8, 9 and 10 would be in a condition for allowance if rewritten as independent claims incorporating the language of the base claims.

Claims 5 was rejected under 35 U.S.C. 112, second paragraph, as being allegedly indefinite for failing to particularly point out and distinctly claim the subject which applicant regards as the invention.

Although Applicant respectfully disagrees with the position taken in the office action, claim 5 has been amended to replace the phrase "optionally substituted nitrogen" with "nitrogen" in the definition of variables T, U and V in order to expedite prosecution.

Applicants preserve the right to pursue compounds of claim 5 in this or a subsequent application in which one or more of T, U, or V is chosen to be a substituted nitrogen.

Claim 5 was rejected under 35 U.S.C. §112, second paragraph, as being allegedly indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A. Rosowsky
U.S.S.N.: 09/890,112
Page 13

Thus, claim 5, as amended, is fully compliant with the requirements of 35 U.S.C. §112 including the requirements of §112, second paragraph.

Claims 11, 12, 14-26, and 28-34 were rejected under 35 U.S.C. §112, first paragraph, because the specification allegedly does not provide enablement for treating patients "susceptible to a" disease.

Although Applicants respectfully disagree with the position taken by the Office Action, claims 11, 12, and 18-21 have been amended to delete the language "or susceptible to". Applicants reserve the right to pursue claims directed to methods of treating patients who are susceptible to infection in this or a subsequent application.

Thus, claims 11, 12, 14-26, and 28-33 are fully compliant with 35 U.S.C. §112 including the requirements of §112, first paragraph.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,

July 12, 2004


John B. Alexander, Ph.D. (Reg. No. 48,399)
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice
Edwards & Angell, LLP
P.O. Box 55874
Boston, MA 02205
Tel: 617-517-5555
Fax: 617-439-4170